References
- Koksal H. The clinical utility of autoantibodies in patients with idiopathic granulomatous mastitis. J Invest Surg. 2020:1–5. doi:https://doi.org/10.1080/08941939.2020.1861666.
- Saydam M, Yilmaz KB, Sahin M, et al. New findings on autoimmune etiology of idiopathic granulomatous mastitis: serum IL-17, IL-22 and IL-23 levels of patients. J Invest Surg. 2020:1–5. doi:https://doi.org/10.1080/08941939.2020.1725190.
- Yigitbasi MR, Guntas G, Atak T, Sonmez C, Yalman H, Uzun H. The role of interleukin-33 as an inflammatory marker in differential diagnosis of idiopathic granulomatous mastitis and breast cancer. J Invest Surg. 2017;30(4):272–276. doi:https://doi.org/10.1080/08941939.2016.1240270.
- Çetin K, Sıkar HE, Güllüoğlu BM. Idiopathic granulomatous mastitis with erythema nodosum: is it a variant of clinical presentation indicating treatment resistance? A retrospective cohort study. Breast J. 2020;26(9):1645–1651. doi:https://doi.org/10.1111/tbj.13944.
- Kehribar DY, Duran TI, Polat AK, Ozgen M. Effectiveness of methotrexate in idiopathic granulomatous mastitis treatment. Am J Med Sci. 2020;360(5):560–565. doi:https://doi.org/10.1016/j.amjms.2020.05.029.
- Grygiel-Gorniak B, Rogacka N, Puszczewicz M. Antinuclear antibodies in healthy people and non-rheumatic diseases - diagnostic and clinical implications. Reumatologia. 2018;56(4):243–248. doi:https://doi.org/10.5114/reum.2018.77976.